Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 12/20 | 0.52 |
| ▸ | ARG2 | P78540 | 11/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ODC1 | P11926 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 3/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5178172 | 0.95 | ARG1 (0.48) | ARG1ARG2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL6129347 | 0.95 | ARG2 (0.53) | ARG1ARG2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL14088071 | 0.95 | ARG2 (0.53) | ARG1ARG2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL23010905 | 0.95 | ARG1 (0.48) | ARG1ARG2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL16887806 | 0.93 | ARG2 (0.52) | ARG1ARG2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL11414745 | 0.93 | ARG2 (0.52) | ARG1ARG2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL7087301 | 0.93 | ARG2 (0.55) | ARG1ARG2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL3024369 | 0.91 | ARG2 (0.53) | ARG1ARG2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL21219814 | 0.91 | ARG2 (0.53) | ARG1ARG2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL8719171 | 0.91 | ARG2 (0.53) | ARG1ARG2MEN1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5543414-A | VIRICIDES | SYNTEX (USA) INC. (US) | 1996-08-06 | — | — | US | claimed |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | GENEFRONTIER CORPORATION (JP) | 2026-03-03 | — | — | US | disclosed |
| CN-120647053-A | Sewage recycling treatment and emission reduction method for circulating cooling water of water-cooled machine room | 嘉兴沃特泰科环保科技股份有限公司 | 2025-09-16 | — | — | CN | disclosed |
| EP-4043076-B1 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | GENEFRONTIER CORP (JP) | 2024-06-26 | — | — | EP | disclosed |
| US-20240200049-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR MAKING POLYPEPTIDES WITH MANY INSTANCES OF NONSTANDARD AMINO ACIDS | YALE UNIVERSITY | 2024-06-20 | — | — | US | disclosed |
| EP-3146977-B1 | TFPI INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-08 | — | — | EP | disclosed |
| CN-117986808-A | Corrosion-resistant cable | 天昕线缆有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20240092836-A1 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | GENEFRONTIER CORPORATION (JP) | 2024-03-21 | — | — | US | disclosed |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIB VZW (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIB VZW (BE) | 2024-01-16 | — | — | US | disclosed |
| EP-0759917-A1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES, INC. (US) | 1997-03-05 | — | — | EP | disclosed |
| US-5591851-A | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1996026933-A9 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | — | 1996-11-28 | — | — | WO | disclosed |
| WO-1996026933-A1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES, INC. (US) | 1996-09-06 | — | — | WO | disclosed |
| WO-1996023801-A2 | NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME | GILEAD SCIENCES, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| US-5543414-A | VIRICIDES | SYNTEX (USA) INC. (US) | 1996-08-06 | — | — | US | disclosed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092836-A1 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | CXCL10, CXCR3, CXCR6 | ARG1 209/4885ARG2 1044/4885MEN1 594/4885 |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | CXCL10, MLX, MICA | ARG1 61/4885ARG2 469/4885MEN1 350/4885 |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIP, MMP8, SLC11A2 | ARG1 40/4885ARG2 359/4885MEN1 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.